SOT: Supportive Oligonucleatide Technique

SOT Therapy Explained

In the realm of modern medical science, innovative therapies continue to emerge, offering new hope for treating previously challenging conditions. One of the most promising advancements in this field is Supportive Oligonucleotide Technique (SOT), which utilizes synthetic oligonucleotides to provide targeted support for various biological processes within the body. This article explores the fundamentals of SOT, its applications across different medical domains, and includes a look into the pioneering work of RGCC (Research Genetic Cancer Centre) lab in advancing oligonucleotide-based therapies.

Understanding Oligonucleotides

Oligonucleotides are short sequences of nucleotides, the fundamental building blocks of DNA and RNA. In the context of SOT, these synthetic molecules are carefully designed and modified to interact with specific cellular processes, offering precise therapeutic interventions.

How SOT Works

Targeted Intervention at the Molecular Level

SOT functions by targeting and modulating key molecular mechanisms involved in disease processes. This can include regulating gene expression, altering RNA function, or influencing protein production. The specificity of oligonucleotides allows for tailored treatments that aim to minimize adverse effects while maximizing therapeutic efficacy.

Types of Supportive Oligonucleotide Therapies

  1. Antisense Oligonucleotides (ASOs): These molecules bind to complementary RNA sequences, thereby modulating RNA splicing, stability, or translation. ASOs have shown promise in treating genetic disorders where abnormal RNA processing contributes to disease pathology.

  2. Small Interfering RNA (siRNA): siRNAs can silence specific genes by inducing RNA interference (RNAi), a natural cellular process that degrades mRNA molecules before they can be translated into proteins. This approach is particularly relevant for conditions characterized by overactive genes.

  3. Aptamers: These are single-stranded oligonucleotides that bind with high affinity and specificity to target molecules such as proteins or small molecules. Aptamers can be used to block harmful protein activities or to deliver therapeutic agents directly to diseased cells.

Applications of SOT

Infectious Diseases

Infectious diseases, both emerging and chronic, pose ongoing challenges in healthcare. SOT approaches, including siRNAs targeting viral genomes or aptamers blocking essential viral proteins, represent innovative strategies for combating pathogens and reducing their impact on global health.

Viral Infections:

– EBV (Epstein Barr Virus)
– CMV (cytomegalovirus)
– Coxsackie virus (Types A & B)
– VZV (Varicella Zoster virus (chicken pox, shingles))
– HHV1/HSV1 (oral herpes virus) – HHV2/HSV2 (genital herpes virus) – HHV6 (Types A & B) (human herpes virus 6)
– HPV (16/18) (human papillomavirus) – HPV (6/11) (human papillomavirus)
– HTLV1 (Human T-cell lymphotropic Virus)
– HBV (Hepatitis B Virus)
– HCV (Hepatitis C Virus)
– HIV (Human Immunodeficiency Virus)

Lyme Disease Assocatied:
- Borrelia mayonii
– Borrelia burgdorferi
– Borrelia garinii
– Borrelia bissettii
– Borrelia bavariensis
– Borrelia miyamotoi
– Candidatus Borrelia tachyglossi
– Borrelia valaisiana
– Borrelia afzelii
– Borrelia finlandensis
– Borrelia recurrentis
– Bartonella henselae
– Bartonella bacilliformis
– Bartonella vinsonii
– Bartonella quintana
– Babesia microti
– Babesia bigemina
– Babesia divergens
– Babesia duncani
– Babesia bovis

Cancer

Cancer has become a prevalent disease. SOT shows promoising results to support targeted cancer care. By targeting specific athways this can help aid as an adjunctive therapy. The aim is to target CTC or circulating tumor cells.

Advantages of SOT

Precision Medicine

SOT exemplifies the principles of precision medicine by delivering therapies tailored to individual genetic profiles and disease characteristics. This personalized approach aims to enhance treatment efficacy while minimizing adverse effects on patients.

Potential for Combination Therapies

Oligonucleotide therapies can be combined with existing treatments such as conventional drugs or gene therapy. This synergistic approach may lead to enhanced therapeutic outcomes, particularly in complex diseases with multifaceted underlying causes.

RGCC Lab: Pioneering Oligonucleotide Therapies

Research Genetic Cancer Centre (RGCC) lab has been at the forefront of developing and refining oligonucleotide-based therapies. With a focus on personalized medicine and innovative treatment approaches, RGCC has contributed significantly to the advancement of SOT for cancer and other diseases. Their research spans the development of novel oligonucleotide constructs, optimization of delivery methods, and clinical trials aimed at validating the safety and efficacy of these therapies.

Challenges and Considerations of SOT Therapy

Delivery Methods

Delivery methods for SOT typically reside in intravenous applications of your targets SOT. First, blood is drawn in the office and sent to the RGCC lab. Once recvied your specific SOT is created and sent back to your practitioner. Once back in office a simple IV infusion is administered to start your care.

Safety and Off-Target Effects of SOT

While highly specific, oligonucleotide therapies can potentially interact with unintended targets, leading to off-target effects. Rigorous preclinical testing and optimization of oligonucleotide design are essential to mitigate these risks and ensure the safety of SOT treatments.

Possible side effects when receiving SOT therapy is low grade fever, headaches, body aches, fatigue, diarrhea and flu-like symptoms. These typically can happen 24-48 hours after a procedure. In some cases when detox is happen a "herx" reaction can occur.

In patients undergoing therapy for cancer it is important to fully access the stage and size of the cancer. Treating cancers that are further progressed can lead to tumor lysis syndrome.

Cost of SOT Therapy

The initial consult for SOT Therapy is $200, this is to review your history

Labs required for workup are needed and these costs will be paid directly to the lab + $50 blood draw fee in office.

SOT Therapy is $2500 for the intravenous infusion that will last 3-9 months.

Conclusion

Supportive Oligonucleotide Therapy represents a paradigm shift in medical treatment, offering targeted solutions to complex diseases at the molecular level. With the pioneering work of institutions like RGCC lab and ongoing advancements in research and technology, SOT has the potential to significantly improve patient outcomes and address previously untreatable conditions. As we look ahead, the integration of SOT into clinical practice promises to usher in a new era of personalized medicine, where therapies are tailored to individual genetic profiles and disease characteristics, ultimately enhancing the quality of life for patients worldwide.

Book Now